Conference Proceedings

A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)

Kim N Chi, Dana E Rathkopf, Gerhardt Attard, Matthew Raymond Smith, Eleni Efstathiou, David Olmos, Eric Jay Small, Ji Youl Lee, Paul R Sieber, Curtis Dunshee, Deborah S Ricci, Jason S Simon, Xin Zhao, Nishi Kothari, Shinta Cheng, Shahneen Kaur Sandhu

JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2020

Grants

Funding Acknowledgements

Janssen Research and Development.